The story of the career of Alan Watt. A successful chemist who became a serial entrepreneur. A not-to-miss event from EPOC
Alan has over 30 years’ experience in drug discovery and development in both the Pharmaceutical and Biotech sectors. He has held senior roles in Pharma (Merck, GSK), Biotech (Cellzome, Trident Biopharma, Bicycle Therapeutics) and as an entrepreneur has founded a number of science-based companies (Elemental Thinking, Autophagix, Xenovium, XenoVida).
His Pharma roles have taken him from Head of Drug Metabolism and Head of In Vivo Pharmacology at Merck, through Head of Preclinical Development for the Neurology Centre of Excellence for Drug Discovery (CEDD) at GSK. In 2008 he moved within GSK to the Immuno-inflammation CEDD, to start-up and head the Pattern Recognition Receptor Discovery Performance Unit (DPU), developing drugs for disorders of the innate immune system. In 2010 he joined Cellzome as VP of Therapeutics where he successfully led the company’s immunology drug discovery efforts and contributed to the successful exit to GSK in 2012. In 2013 Alan established Xenovium to work in partnership with Pharma and Biotech clients and additionally joined Bicycle Therapeutics as VP of Therapeutics in 2015. His latest venture, XenoVida, delivering biochemical and behavioural profiling to the weight management market, will launch in late 2016.
He holds a PhD in Drug Metabolism, an MBA from the Open Business School, a BSc in Chemistry and has over 50 peer-reviewed scientific publications. Alan also works in the voluntary sector as a Trustee of the Babraham Institute (BI), an independent charitable life sciences institute involved in biomedical research and as a Director of Babraham Institute Enterprise, the commercial arm of the Babraham Institute.
Please click here to register for the event.
